The market performance of Lineage Cell Therapeutics Inc has been somewhat unstable. Over the past year, the company’s stock achieved a high of $1.61 on 03/28/24, with the lowest value for the same timeframe being $0.77, recorded on 08/14/24.
52-week price history of LCTX Stock
Analyzing the 52-week price history of a stock, including its high and low prices, can provide valuable insight into its current status and potential future performance. Lineage Cell Therapeutics Inc’s current trading price is -47.94% away from its 52-week high, while its distance from the 52-week low is 9.35%. The stock’s price range for this period has remained between $0.77 and $1.61. The Healthcare sector company’s shares managed to surpass a trading volume of around 0.63 million for the day, which was noticeably higher compared to the shares’ average daily volume of 0.47 million over the last three months.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Financial Performance and Market Capitalization
Lineage Cell Therapeutics Inc (LCTX) has experienced a quarterly decline of -16.18% in its revenues when compared to the same period in the previous year. Presently, the company has a total market capitalization of 158.29M and boasts a workforce of 75 employees.
Moving average and trading volume data
Based on Barchart.com data, the company’s moving average over the 100-day period was 0.9254, with a change in price of -0.2118. Similarly, Lineage Cell Therapeutics Inc recorded 645,742 in trading volume during the last 100 days, posting a change of -20.17%.
LCTX Debt-to-equity ratio analysis
The debt-to-equity (D/E) ratio is a valuable metric that offers insight into a company’s financial health and standing in the market. This ratio is calculated by dividing a company’s current total liabilities by its shareholders’ equity. The D/E ratio illustrates the extent of debt a company is utilizing to support its assets in relation to the value of its shareholders’ equity. At the time of writing, the total D/E ratio for LCTX stands at 0.04. Similarly, the long-term debt-to-equity ratio is also 0.03.
LCTX Stock Stochastic Average
As of today, the raw stochastic average of Lineage Cell Therapeutics Inc over the last 50 days is at 35.23%. This shows a increasee from the raw stochastic average of the previous 20 days, which was recorded at 30.60%. Further, the company’s Stochastic %K and %D values for the last 20 days were 35.90% and 37.24%, respectively.
LCTX Stock Price Performance Analysis
The stock price performance for the year has been a mixed bag, indicating either a pessimistic or optimistic outlook depending on how you look at it. Until today this year the stock’s price performance recorded a decrease of -23.10%. However, over the last six months, the performance has been stronger by -30.15%. The price of LCTX decreased -4.75% over the last 30 days. And in the last five days, it has fallen by -0.82%.
